Inogen, Inc.

NasdaqGS:INGN Stok Raporu

Piyasa değeri: US$190.7m

Inogen Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Inogen şirketinin kazançları yıllık ortalama -17.5% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 10.4% oranında artan oldu. Gelirler yıllık ortalama 0.1% oranında artan oldu.

Anahtar bilgiler

-17.55%

Kazanç büyüme oranı

-16.53%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi8.90%
Gelir büyüme oranı0.11%
Özkaynak getirisi-11.83%
Net Marj-6.52%
Sonraki Kazanç Güncellemesi07 May 2026

Yakın geçmiş performans güncellemeleri

Recent updates

INGN: Buybacks And New Leadership Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power

Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside

Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).

INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power

Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.

INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares

Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.

INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead

Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.

INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence

Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).

INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead

Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.

INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve

Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.

INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging

Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.

Slow Progress At Inogen ... But Progress All The Same

Nov 11

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.

There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

Aug 31
There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

May 10
Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report
User avatar

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Mar 08
Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

A Volatile Share Price Masks Some Of The Progress At Inogen

Mar 01

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Feb 28
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Jan 22
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen: Upside Seems Limited After Big Move Up

Sep 24

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Jul 16
Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Inogen: Improving, But Still Struggling For Air

Jul 01

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

May 22
Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Apr 13

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Mar 01
Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Feb 01
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Gelir ve Gider Dağılımı

Inogen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:INGN Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
31 Dec 25349-2316519
30 Sep 25347-2516620
30 Jun 25343-2616819
31 Mar 25340-2716919
31 Dec 24336-3617222
30 Sep 24332-5317422
30 Jun 24327-9217023
31 Mar 24322-9716822
31 Dec 23316-10217021
30 Sep 23328-13317020
30 Jun 23349-9617820
31 Mar 23369-9018222
31 Dec 22377-8418022
30 Sep 22366-5017921
30 Jun 22353-2817020
31 Mar 22351-2016718
31 Dec 21358-616217
30 Sep 213561115516
30 Jun 21337-214715
31 Mar 21307-513614
31 Dec 20308-613614
30 Sep 20313-213514
30 Jun 20331613613
31 Mar 203601414111
31 Dec 19362211429
30 Sep 19370321448
30 Jun 19373421487
31 Mar 19369461447
31 Dec 18358521347
30 Sep 18335411207
30 Jun 18309321076
31 Mar 1827626965
31 Dec 1724921885
30 Sep 1723727815
30 Jun 1722225765
31 Mar 1721224725
31 Dec 1620321695
30 Sep 1619219675
30 Jun 1617917645
31 Mar 1616813604
31 Dec 1515912574
30 Sep 151489534
30 Jun 151369493

Kaliteli Kazançlar: INGN şu anda kârlı değil.

Büyüyen Kar Marjı: INGN şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: INGN kârlı değildir ve zararlar son 5 yılda yılda 17.5% oranında artmıştır.

Büyüme Hızlandırma: INGN 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: INGN kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 13.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: INGN hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.83% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

7D

1Y

7D

1Y

7D

1Y

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/04 19:32
Gün Sonu Hisse Fiyatı2026/05/01 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Inogen, Inc. 9 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Anderson SchockB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker
Matthew MishanKeyBanc Capital Markets Inc.